Table 3.
Ongoing clinical trials of targeted therapy in cholangiocarcinomaa.
| Drug | Targets | Phase | Combination | Trial number |
|---|---|---|---|---|
| DRIVER MUTATIONS | ||||
| Dasatinib | IDH1/2 | II | NCT02428855 | |
| AG-120 | IDH1 | I, III | NCT02073994, NCT02989857 | |
| Metformin | IDH1/2 | I/II | Chloroquine | NCT02496741 |
| Varlitinib | EGFR (ErbB-1), Her-2/neu (ErbB-2) | II | NCT02609958 | |
| Leucovorin and nal-IRI | EGFR, KRAS | II | 5-FU | NCT03043547 |
| Niraparib | BAP1 | II | NCT03207347 | |
| Merestinib | c-Met, HGFR | I | Gemcitabine + Cisplatin | NCT03027284 |
| LOXO-195 | NTRK1, NTRK2, NTRK3 | I/II | NCT03215511 | |
| Trastuzumab Emtansine | HER2 | II | NCT02999672 | |
| DKN-01 | Wnt, DKK1 | I | Gemcitabine + Cisplatin | NCT02375880 |
| Copanlisib (BAY 80-6946) | PI3K signaling pathway | II | Gemcitabine + Cisplatin | NCT02631590 |
| Panitumumab | EGF | II | Gemcitabine + Irinotecan | NCT00948935 |
| FUSION GENE | ||||
| ARQ 087 | FGFR2 | I/II, II | NCT01752920, NCT03230318 | |
| BGJ398 | FGFR2 | II | NCT02150967 | |
| INCB054828 | FGFR2 | II | NCT02924376 | |
| H3B-6527 | FGFR4 | I | NCT02834780 | |
| Erdafitinib | FGFR | II | NCT02699606 | |
| Ceritinib (LDK378) | ROS1, ALK | II | NCT02638909, NCT02374489 | |
| INCB062079 | FGFR4, FGF19 | I | NCT03144661 | |
| Entrectinib | ROS1, ALK TrkA, TrkB, TrkC | II | NCT02568267 | |
| LOXO-101 | NTRK fusion | II | NCT02576431 | |
| ANGIOGENESIS | ||||
| Apatinib | VEGFR-2 | III | NCT03251443 | |
| Ramucirumab | VEGFR-2 | II | NCT02520141 | |
| Regorafenib | VEGFR, RET, RAF-1, KIT, PDGFRB, FGFR1, TIE2, BRAF(V600E) | II | NCT02053376 | |
| Pazopanib | VEGF, PDGFR, FGFR, KIT | II | Gemcitabine | NCT01855724 |
| VEGFR/PDGFR/Raf MEK MAPK/ERK | I | GSK1120212 | NCT01438554 | |
| CHECKPOINT INHIBITOR | ||||
| Durvalumab (MEDI 4736) | PD-L1, PD-1 | I | Guadecitabine (SGI-110) | NCT03257761 |
| Pembrolizumab | PD-1 | II | Peginterferon alpha-2b (Sylatron) | NCT02982720 |
| PD-L1, PD-L2 HSP90 | I | XL888 | NCT03095781 | |
| Atezolizumab | PD-L1 | II | Cobimetinib | NCT03201458 |
| PD-L1 | I | Gemcitabine+ Cisplatin | NCT03267940 | |
| Nivolumab | PD-1, PD-L1 HDAC inhibitor | II | Entinostat | NCT03250273 |
| CTLA-4 PD-1 | II | Ipilimumab | NCT02834013 | |
| ABBV-181 | PD-1, PD-L1 | I | Rovalpituzumab Tesirine | NCT03000257 |
| ABBV-368 | OX40 | I | Monotherapy or combination with ABBV-181 | NCT03071757 |
| OTHER PATHWAYS | ||||
| RRx-001 | G6PD | II | Gemcitabine + Cisplatin | NCT02452970 |
| CX-4945 | CK2 | I/II | Gemcitabine + Cisplatin | NCT02128282 |
| Melphalan/HDS | Induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. | II/III | Gemcitabine + Cisplatin | NCT03086993 |
| BBI503 | Cancer stem cell (CSC) | II | NCT02232633 | |
| Acelarin (NUC-1031) | dFdCDP, dFdCTP | I | Cisplatin | NCT02351765 |
| CX-2009 | Tumor-associated antigen (TAA) CD166 | I/II | NCT03149549 | |
a
Information acquired from Clinicaltrials.gov.